Stephanie Ho1, Lynn Nguyen2, Trang Trinh1, Conan MacDougall3. 1. University of California San Francisco School of Pharmacy, 533 Parnassus Ave, U-503 Box 0622, San Francisco, CA, 94143, USA. 2. University of California San Francisco Medical Center, San Francisco, CA, USA. 3. University of California San Francisco School of Pharmacy, 533 Parnassus Ave, U-503 Box 0622, San Francisco, CA, 94143, USA. conan.macdougall@ucsf.edu.
Abstract
PURPOSE OF REVIEW: To describe the mechanisms and clinical relevance of emergent resistance to three recently introduced beta-lactamase inhibitor combinations (BLICs) active against resistant Gram-negative organisms: ceftolozane-tazobactam, ceftazidime-avibactam, and meropenem-vaborbactam. RECENT FINDINGS: Despite their recent introduction into practice, clinical reports of resistance to BLICs among typically susceptible organisms have already emerged, in some cases associated with therapeutic failure. The resistance mechanisms vary by agent, including mutations in beta-lactamase active sites, upregulation of efflux pumps, and alterations in the structure or expression of porin channels. These changes may confer cross-resistance or, rarely, increased susceptibility to related agents. Clinicians need to be aware of the potential for initial or emergent resistance to BLICs and ensure appropriate antimicrobial susceptibility testing is performed. Dose optimization and novel combinations of agents may play a role in preventing and managing resistance. Recently approved BLICs have provided important new therapeutic options against resistant Gram-negative organisms, but are already coming up against emergent resistance. Awareness of the potential for resistance, early detection, and dose optimization may be important in preserving the utility of these agents.
PURPOSE OF REVIEW: To describe the mechanisms and clinical relevance of emergent resistance to three recently introduced beta-lactamase inhibitor combinations (BLICs) active against resistant Gram-negative organisms: ceftolozane-tazobactam, ceftazidime-avibactam, and meropenem-vaborbactam. RECENT FINDINGS: Despite their recent introduction into practice, clinical reports of resistance to BLICs among typically susceptible organisms have already emerged, in some cases associated with therapeutic failure. The resistance mechanisms vary by agent, including mutations in beta-lactamase active sites, upregulation of efflux pumps, and alterations in the structure or expression of porin channels. These changes may confer cross-resistance or, rarely, increased susceptibility to related agents. Clinicians need to be aware of the potential for initial or emergent resistance to BLICs and ensure appropriate antimicrobial susceptibility testing is performed. Dose optimization and novel combinations of agents may play a role in preventing and managing resistance. Recently approved BLICs have provided important new therapeutic options against resistant Gram-negative organisms, but are already coming up against emergent resistance. Awareness of the potential for resistance, early detection, and dose optimization may be important in preserving the utility of these agents.
Authors: Antoni Torres; Nanshan Zhong; Jan Pachl; Jean-François Timsit; Marin Kollef; Zhangjing Chen; Jie Song; Dianna Taylor; Peter J Laud; Gregory G Stone; Joseph W Chow Journal: Lancet Infect Dis Date: 2017-12-16 Impact factor: 25.071
Authors: Maria F Mojica; Christopher P Ouellette; Amy Leber; M Brian Becknell; Monica I Ardura; Federico Perez; Masako Shimamura; Robert A Bonomo; Samuel L Aitken; Samuel A Shelburne Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink Journal: Clin Infect Dis Date: 2016-06-16 Impact factor: 9.079
Authors: G L Drusano; Robert A Bonomo; Steven M Marshall; Laura J Rojas; Mark D Adams; Maria F Mojica; Barry N Kreiswirth; Liang Chen; Nino Mtchedlidze; Meredith Bacci; Michael Vicchiarelli; Jürgen B Bulitta; Arnold Louie Journal: Antimicrob Agents Chemother Date: 2021-05-18 Impact factor: 5.191
Authors: Olga Lomovskaya; Ruslan Tsivkovski; Dongxu Sun; Raja Reddy; Maxim Totrov; Scott Hecker; David Griffith; Jeffery Loutit; Michael Dudley Journal: Front Microbiol Date: 2021-07-05 Impact factor: 5.640